Assignee
CT INMUNOLOGIA MOLECULAR
CU·10 granted patents·12 pending applications·6 citations·filing 2000–2024
Top patents by PatentIndex Score
22 records- 0173US11806396B2Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccinesCT INMUNOLOGIA MOLECULAR·Filed 2018·Granted Nov 7, 2023·1 cites·18 claims
- 0269US12280109B2Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccinesCT INMUNOLOGIA MOLECULAR·Filed 2023·Granted Apr 22, 2025·0 cites·24 claims
- 0359US2025179139A1Human interleukin-2-derived muteins with superagonist activityCT INMUNOLOGIA MOLECULAR·Filed 2023·Application pending·0 cites
- 0458US2024033302A1Ganglioside gm3-containing nanoparticles as immunomodulatorsCT INMUNOLOGIA MOLECULAR·Filed 2023·Application pending·0 cites
- 0557US6891023B1Antibodies and Fv fragment recognizing antigen IOR C2CT INMUNOLOGIA MOLECULAR·Filed 2000·Granted May 10, 2005·5 cites·12 claims
- 0657US2024299518A1Method for the treatment of patients with carcinomasCT INMUNOLOGIA MOLECULAR·Filed 2024·Application pending·0 cites
- 0754US11766462B2Ganglioside GM3-containing nanoparticles as immunomodulatorsCT INMUNOLOGIA MOLECULAR·Filed 2018·Granted Sep 26, 2023·0 cites·6 claims
- 0851US2024279348A1Use of monoclonal antibodies against the epidermal growth factor receptor in the treatment of patients with hypoxemic acute respiratory failureCT INMUNOLOGIA MOLECULAR·Filed 2022·Application pending·0 cites
- 0949US2025049890A1Fusion proteins composed of an antibody and a muteinCT INMUNOLOGIA MOLECULAR·Filed 2022·Application pending·0 cites
- 1048US11926654B2Fusion proteins composed of an interleukin-2 mutein and type I interferonCT INMUNOLOGIA MOLECULAR·Filed 2019·Granted Mar 12, 2024·0 cites·17 claims
- 1147US2023256069A1Use of epidermal growth factor depleting agents in the treatment of chronic obstructive pulmonary diseaseCT INMUNOLOGIA MOLECULAR·Filed 2021·Application pending·0 cites
- 1247US2024374695A1Vaccine compositions depleting hematopoietic growth factors for the treatment of inflammatory diseasesCT INMUNOLOGIA MOLECULAR·Filed 2022·Application pending·0 cites
- 1345US12019073B2Method for the treatment of patients with carcinomasCT INMUNOLOGIA MOLECULAR·Filed 2018·Granted Jun 25, 2024·0 cites·3 claims
- 1444US2019275132A1Divalent vaccine compositions and the use thereof for treating tumorsCT INMUNOLOGIA MOLECULAR·Filed 2019·Application pending·0 cites
- 1544US2017066835A1Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritisCT INMUNOLOGIA MOLECULAR·Filed 2016·Application pending·0 cites
- 1643US2023226163A1Inorganic nanoparticle-based vaccine compositions for cancer treatmentCT INMUNOLOGIA MOLECULAR·Filed 2021·Application pending·0 cites
- 1741US2022152107A1Method for expansion and differentiation of t lymphocytes and nk cells for adoptive transfer therapiesCT INMUNOLOGIA MOLECULAR·Filed 2020·Application pending·0 cites
- 1840US9701730B2TGFβ-derived polypeptides and uses thereofCT INMUNOLOGIA MOLECULAR·Filed 2013·Granted Jul 11, 2017·0 cites·14 claims
- 1933US12569540B2Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereofCT INMUNOLOGIA MOLECULAR·Filed 2020·Granted Mar 10, 2026·0 cites·6 claims
- 2026US2021060127A1Use of the basic form of recombinant human erythropoietin in the treatment of a patients with spinocerebellar ataxia with cag repeat mutationsCT INMUNOLOGIA MOLECULAR·Filed 2017·Application pending·0 cites
- 2125US12312388B2Method for increasing the secretion levels of interleukin 2 and muteins thereof by introducing a point mutationCT INMUNOLOGIA MOLECULAR·Filed 2017·Granted May 27, 2025·0 cites·18 claims
- 2224US9527920B2Recombinant antibodies having dual specificity for gangliosides and use thereofCT INMUNOLOGIA MOLECULAR·Filed 2013·Granted Dec 27, 2016·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when CT INMUNOLOGIA MOLECULAR files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →